Energenesis Biomedical Co (TPE:6657) Selling, General, & Admin. Expense: NT$88.11 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6657 Energenesis Biomedical Co Ltd TPE:6657
61 GF Score
Price NT$30.65
GF Value NT$51.49
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Energenesis Biomedical Co Selling, General, & Admin. Expense?

Energenesis Biomedical Co TPE:6657 -2.85% 61 Selling, General, & Admin. Expense is NT$88.11 Mil as of Mar. 2026. GuruFocus rates TPE:6657 with a GF Score™ of 61/100 and a GF Value™ of NT$51.49 (Possible Value Trap). The stock has 2 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Energenesis Biomedical Co's selling, general, & admin. expense for the three months ended in Mar. 2026 was NT$23.29 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was NT$88.11 Mil.


Energenesis Biomedical Co  (TPE:6657) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Energenesis Biomedical Co Selling, General, & Admin. Expense Related Terms


Energenesis Biomedical Co Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Energenesis Biomedical Co's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Energenesis Biomedical Co Selling, General, & Admin. Expense Chart

Energenesis Biomedical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.69 63.14 81.94 81.01 86.68

Energenesis Biomedical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.86 20.57 20.34 23.92 23.29

TPE:6657 vs VRTX, REGN, RVMD: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Energenesis Biomedical Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Energenesis Biomedical Co Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Energenesis Biomedical Co's Selling, General, & Admin. Expense falls into.


TPE:6657
61GF Score
Energenesis Biomedical Co Ltd TPE:6657
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Energenesis Biomedical Co Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$88.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of NT$88.11 Mil mean?
Energenesis Biomedical Co (TPE:6657) has a Selling, General, & Admin. Expense of NT$88.11 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Energenesis Biomedical Co and its competitors.
Is Energenesis Biomedical Co's Selling, General, & Admin. Expense too high?
Energenesis Biomedical Co's current Selling, General, & Admin. Expense is NT$88.11 Mil. Overall, Energenesis Biomedical Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's Selling, General, & Admin. Expense compare to VRTX and REGN?
Energenesis Biomedical Co's Selling, General, & Admin. Expense of NT$88.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Energenesis Biomedical Co and its competitors. Energenesis Biomedical Co's current Selling, General, & Admin. Expense is NT$88.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.49, compared to a current price of NT$30.65 — trading 40.5% below its estimated fair value. The current Selling, General, & Admin. Expense is NT$88.11 Mil. Energenesis Biomedical Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current Selling, General, & Admin. Expense is NT$88.11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?

Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued. The current stock price of NT$30.65 is trading 40.5% below its estimated GF Value™ of NT$51.49. GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.

Key valuation signals for TPE:6657:

  • Selling, General, & Admin. Expense: NT$88.11 Mil
  • GF Value™: NT$51.49 vs. price of NT$30.65 (40.5% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Energenesis Biomedical Co Business Description

Address No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
61GF Score

Get the complete analysis for TPE:6657

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.65
Price
NT$51.49
GF Value